New approach eradicates breast cancer in mice

Date

07/23/21
Researchers on the study include, front from left, Chengjian Mao, Matthew Boudreau, Darjan Duraki and Ji Eun Kim, and back from left, professors Erik Nelson, Paul Hergenrother and David Shapiro.

By Diana Yates, Life Sciences Editor


A new approach to treating breast cancer kills 95-100 percent of cancer cells in mouse models of human estrogen-receptor-positive breast cancers and their metastases in bone, brain, liver and lungs. The newly developed drug, called ErSO, quickly shrinks even large tumors to undetectable levels.

Led by scientists at the University of Illinois Urbana-Champaign, the research team reports the findings in the journal Science Translational Medicine.

“Even when a few breast cancer cells do survive, enabling tumors to regrow over several months, the tumors that regrow remain completely sensitive to retreatment with ErSO,” said UIUC biochemistry professor David Shapiro, who led the research with Illinois chemistry professor Paul Hergenrother. “It is striking that ErSO caused the rapid destruction of most lung, bone and liver metastases and dramatic shrinkage of brain metastases, since tumors that have spread to other sites in the body are responsible for most breast cancer deaths,” Shapiro said. (Watch a video about the results.)

 

A computer-drawn image of a molecular structure on a white background
Researchers discovered a small molecule, ErSO, that eradicates breast cancers in mice by targeting a pathway that protects cancer cells. Photo by L. Brian Stauffer

The activity of ErSO depends on a protein called the estrogen receptor, which is present in a high percentage of breast tumors. When ErSO binds to the estrogen receptor, it upregulates a cellular pathway that prepares cancer cells for rapid growth and protects them from stress. This pathway, called the anticipatory Unfolded Protein Response, or a-UPR, spurs the production of proteins that protect the cell from harm.

“The a-UPR is already on, but running at a low level, in many breast cancer cells,” Shapiro said. “It turns out that this pathway shields cancer cells from being killed off by anti-cancer drugs.”

Shapiro and former UIUC medical scholar Neal Andruska first identified the a-UPR pathway in 2014 and reported the development of a compound that pushed the a-UPR pathway into overdrive to selectively kill estrogen-receptor-containing breast cancer cells.

“Because this pathway is already on in cancer cells, it’s easy for us to overactivate it, to switch the breast cancer cells into lethal mode,” said graduate student Darjan Duraki, who shares first-author status on the new report with graduate student Matthew Boudreau.

While the original compound prevented breast cancer cells from growing, it did not rapidly kill them, and it had undesirable side effects. For the new research, Shapiro and Hergenrother worked together on a search for a much more potent small molecule that would target the a-UPR. Their analysis led to the discovery of ErSO, a small molecule that had powerful anticancer properties without detectable side effects in mice, further tests revealed.

“This anticipatory UPR is estrogen-receptor dependent,” Hergenrother said. “The unique thing about this compound is that it doesn’t touch cells that lack the estrogen receptor, and it doesn’t affect healthy cells – whether or not they have an estrogen receptor. But it’s super-potent against estrogen-receptor-positive cancer cells.”

ErSO is nothing like the drugs that are commonly used to treat estrogen-responsive cancers, Shapiro said.

“This is not another version of tamoxifen or fulvestrant, which are therapeutically used to block estrogen signaling in breast cancer,” he said. Even though it binds to the same receptor that estrogen binds, it targets a different site on the estrogen receptor and attacks a protective cellular pathway that is already turned on in cancer cells, he said.

“Since about 75% of breast cancers are estrogen-receptor positive, ErSO has potential against the most common form of breast cancer,” Boudreau said. “The amount of estrogen receptor needed for ErSO to target a breast cancer is very low, so ErSO may also work against some breast cancers not traditionally considered to be ER-positive.”

Further studies in mice showed that exposure to the drug had no effect on their reproductive development. And the compound was well tolerated in mice, rats and dogs given doses much higher than required for therapeutic efficacy, the researchers found.

ErSO also worked quickly, even against advanced, human-derived breast cancer tumors in mice, the researchers report. Often within a week of exposure to ErSO, advanced human-derived breast cancers in mice shrank to undetectable levels.

“Many of these breast cancers shrink by more than 99% in just three days,” Shapiro said. “ErSO is fast-acting and its effects on breast cancers in mice are large and dramatic.”

The pharmaceutical company Bayer AG has licensed the new drug and will explore its potential for further study in human clinical trials targeting estrogen-receptor-positive breast cancers, the researchers said. The researchers will next explore whether ErSO is effective against other types of cancers that contain estrogen receptor.

Study co-authors at UIUC also include veterinary clinical medicine professor Timothy Fan, molecular and integrative physiology professor Erik Nelson, and professor emeritus of pathology Edward Roy. Fan, Hergenrother, Nelson, Shapiro and Roy are affiliates of the Cancer Center at Illinois. Fan, Hergenrother and Nelson also are affiliated with the Carl R. Woese Institute for Genomic Biology at Illinois and Hergenrother and Fan are faculty in the Carle Illinois College of Medicine at UIUC.

Funders of this work include the University of Illinois, the U.S. Department of Defense, the National Institutes of Health, and Systems Oncology. The U. of I. has filed patents on some compounds described in the study.

Editor’s notes

To reach David Shapiro, email djshapir@illinois.edu.

To reach Paul Hergenrother, email hergenro@illinois.edu.

The paper “A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice” is available online and from the U. of I. News Bureau.

DOI: 10.1126/scitranslmed.abf1383

 

Related People

hergenro

Directory

scheelinAlexander
Scheeline
bjmccallBenjamin
McCall
r-gennisRobert
Gennis
j-gerltJohn
Gerlt
sgranickSteve
Granick
mgruebelMartin
Gruebele
hergenroPaul
Hergenrother
huangRaven
Huang
mlkraftMary
Kraft
leckbandDeborah
Leckband
yi-luYi
Lu
martinisSusan
Martinis
snairSatish
Nair
eoldfielEric
Oldfield
cmsCharles
Schroeder
zanZaida
Luthey-Schulten
selvinPaul
Selvin
sksScott
Silverman
s-sligarStephen
Sligar
tajkhorsEmad
Tajkhorshid
zhao5Huimin
Zhao
pbraunPaul
Braun
mdburkeMartin
Burke
jeffchanJefferson
Chan
sdenmarkScott
Denmark
dlottDana
Dlott
foutAlison
Fout
agewirthAndrew
Gewirth
ggirolamGregory
Girolami
sohirataSo
Hirata
jainPrashant
Jain
jkatzeneJohn
Katzenellenbogen
nmakriNancy
Makri
douglasmDouglas
Mitchell
jsmooreJeffrey
Moore
murphycjCatherine
Murphy
r-nuzzoRalph
Nuzzo
dimerPhilip
Phillips
rauchfuzThomas
Rauchfuss
joaquinrJoaquín
Rodríguez-López
sarlahDavid
Sarlah
kschweizKenneth
Schweizer
jsweedleJonathan
Sweedler
vddonkWilfred
van der Donk
renskeRenske
van der Veen
vuraweisJosh
Vura-Weis
mcwhite7M.
White
sczimmerSteven
Zimmerman
beakPeter
Beak
wklemperWalter
Klemperer
jdmcdonaJ.
McDonald
pogoreloTaras
Pogorelov
mshen233Mei
Shen
dewoonDavid
Woon
wboulangWilliam
Boulanger
rxbRohit
Bhargava
qchen20Qian
Chen
jianjuncJianjun
Cheng
hy66Hong
Yang
andinomaJosé
Andino Martinez
decosteDonald
DeCoste
thhuangTina
Huang
tjhummelThomas
Hummel
dkellDavid
Kell
doctorkMichael
Koerner
marvilleKelly
Marville
crrayChristian
Ray
tlbrownTheodore
Brown
rmcoatesRobert
Coates
thdjrThom
Dunning
dykstraClifford
Dykstra
j-jonasJiri
Jonas
j-lisyJames
Lisy
shapleyJohn
Shapley
pshapleyPatricia
Shapley
zumdahl2Steven
Zumdahl
ksuslickKenneth
Suslick
jcoxJenny
Cox
sqdSean
Drummond
sheeleySarah
Sheeley
jsmaddenJoseph
Madden
cknight4Connie
Knight
schulzeHeather
Schulze
kbaumgarKeena
Finney
adkssnBeatrice
Adkisson
trabari1Katie
Trabaris
metclfKara
Metcalf
ljohnso2Lori
Johnson
lchenoweLeslie
Chenoweth
wdedoWolali
Dedo
spinnerDavid
Spinner
plblumPatricia
Simpson
stevens2Chad
Stevens
lsagekarLori
Sage-Karlson
bertholdDeborah
Berthold
kecarlsoKathryn
Carlson
sdesmondSerenity
Desmond
axelson2Jordan
Axelson
scbakerStephanie
Baker
pflotschPriscila
Falagan Lotsch
dgrayDanielle
Gray
thennes2Tom
Hennessey
holdaNancy
Holda
aibarrAlejandro
Ibarra
kimshSung Hoon
Kim
kocherg2Nikolai
Kocherginsky
philipk2Philip
Kocheril
legare2Stephanie
Legare
alewandoAgnieszka
Lewandowska
smccombiStuart
McCombie
jdm5Justin
McGlauchlen
egmooreEdwin
Moore
myerscouKathleen
Myerscough
snalla2Siva
Nalla
romanovaElena
Romanova
roubakhiStanislav
Rubakhin
shvedalxAlexander
Shved
asoudaAlexander
Soudakov
xywangXiying
Wang
kwilhelKaren
Wilhelmsen
wilkeyRandy
Wilkey
silongSilong
Zhang
schlembaMary
Schlembach
trimmellAshley
Trimmell
emccarr2Elise
McCarren
cmercierChristen
Mercier
atimpermAaron
Timperman
niesShuming
Nie
hshanHee-Sun
Han
mmgMutha
Gunasekera
kknightsKatriena
Knights
lisawLisa
Williamson
keinckKatie
Einck
kneef1Kate
Neef
txiang4Tiange
Xiang
j-hummelJohn
Hummel
i-paulIain
Paul
munjanjaLloyd
Munjanja
glnGayle
Nelsen
agerardAnna
Gerard
powerskaKimberly
Powers
lolshansLisa
Olshansky
miricaLiviu
Mirica
qingcao2Qing
Cao
lisa3Lisa
Johnson
tinalambTina
Lamb
baronpBaron
Peters
bransle2Sarah
Bransley
dylanmh2Dylan
Hamilton
raegansRaegan
Smith
apm8Angad
Mehta
leverittJohn
Leveritt
xingwXing
Wang
emillrEva
Miller
jmill24Jacqueline
Miller
jlbass2Julia
Bass
ramonarRamona
Rudzinski
tlcraneTracy
Crane
cejohnstCelia
Johnston
adlAmber
LaBau
cnsolomoCandice
Solomon-Strutz
mikaelbMikael
Backlund
jacksonnNick
Jackson